الأسم : محمود عبد الرحيم محمود الشاعر

Email:a.mahmoud@zu.edu.jo

IT/ CIS

Academic Rank: Professor

Membership:

1	نقابة الصيادلة الأردنيين

Qualifications:

1	درجة البكالوريوس – جامعة العلوم والتكنولوجيا الأردنية 1998
2	درجة الماجستير في العلوم الصيدلانية – الجامعة الأردنية 2000
3	درجة الدكتوراة في تصميم واكتشاف الأدوية 2010

- **Professional Objective(s):**

  تطوير عوامل جديدة مضادة للسرطان باستخدام النمذجة الجزيئية.
- **إنشاء وحدة بحثية في مجال النمذجة الجزيئية وتصميم الأدوية.**
- **التدريس في مجالات الكيمياء الطبية، الكيمياء التحليلية، والكيمياء التخليقية.**
- **إدارة المختبرات العلمية.**

Teaching Experience:

#	From	to	Experience
1	2020	Till now	أستاذ في تصميم واكتشاف الأدوية

2	2015	2020	أستاذ مشارك في تصميم واكتشاف الأدوية
3	2010	2015	أستاذ مساعد في تصميم واكتشاف الأدوية
4	10-9-2010	Till now	محاضر أكاديمي في كلية الصيدلة في جامعة الزرقاء
5	1/10/2006	1/7/2010:	مدرس ومحاضر في كلية الصيدلة في جامعة العلوم التطبيقية
6	14/12/2002	30/6/2006	رئيس قسم الصيدلة في معهد السباعي بالطائف
7	14/12/2001	1/12/2002:	باحث في البحث والتطوير في الشركة العربية لتصنيع الأدوية

Publications:

#	Title	Publisher	Year/ Issue (Vol/No)
1.	Investigation of Antimicrobial Sesquiterpenes in Ferula harmonis F. root	ACTA Technologie et lagis medicamenti	**2000**
2.	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening	European Journal of Medicinal Chemistry	**2010**

	followed by in vitro bioassay		
3.	Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90α Inhibitors	J. Chem. Inf. Model	**2010**
4.	Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation	J Enzyme Inhib Med Chem.	**2010**
5.	Rational exploration of new pyridinium-based HSP90α inhibitors tailored to thiamine structure	Medicinal Chemistry Research	**2012**
6.	Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors	Med Chem Res	**2012**
7.	Application of Docking-Based Comparative Intermolecular Contacts Analysis for Validating Hsp90α Docking Studies and Subsequent In Silico screening for Inhibitors	Journal of Molecular Modeling	**2012**
8.	1-[2-Substituted ethyl]-2-methyl-5-nitroimidazole derivatives, synthesis andantibacterial activities	Der Pharma Chemica	**2013**

9.	Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors	Journal of molecular graphics & modelling	**2013**
10.	Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies	Der Pharma chemica	**2013**
11.	Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors,	The Open Medicinal Chemistry Journal	**2013**
12.	Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.	Journal of Molecular Modeling	**2014**
13.	Could the cancer be a chronic immune disorder? rather than a serious malignant disease	Der Pharma chemica	**2014**
14.	Discovery of nanomolar Phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modelling and virtual screening followed by in vitro analysis	European Journal of Medicinal Chemistry	**2014**
15.	Evaluation of antimicrobial	Der Pharma chemica	**2014**

	activities of synthesized pyridinium derivatives		
16.	Docking and Pharmacophore Mapping of Halogenated Pyridinium Derivatives as Heat Shock Protein90	Journal of Chemical and Pharmaceutical Research	**2015**
17.	Screening of miscellaneous Hsp90 inhibitors using virtual co-crystallized pharmacophore	Journal of Computational Methods in Molecular Design	**2015**
18.	Discovery of Check Point Kinase1 (Chk1) Inhibitors as Potential Anticancer Agents Using Ligand-Based Modelling and Virtual Screening	Journal of In Silico & In Vitro Pharmacology	**2015**
19.	Evaluation of Novel Akt1 Inhibitors as Anticancer Agents using Virtual Co-crystallized Pharmacophore Generation	J Mol Graph Model.	**2015**
20.	Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation	J Enzyme Inhib Med Chem	**2016**
21.	Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening	J Mol Recognit.	**2016**
22	Ligand-based modeling of Akt3 lead to potent dual	J Mol Graph Model	**2018**

	Akt1/Akt3 inhibitor		
23	Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis	Med Chem	**2019**
24	Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents	Comput Biol Chem	**2019**
25	Investigation of binding characteristics of Phosphoinositide-dependent kinase-1 (PDK1) co-crystallized ligands through virtual pharmacophore modeling leading to novel anti - PDK1 hits	Med Chem	**2019**
26	Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents	Anticancer Agents Med Chem	**2020**
27	Combined High Throughput Screening with QSAR Analysis Unravel Potential Glyoxalase-I inhibitors	Curr Comput Aided Drug Des	**2020**

28	Elaboration of Novel TTK1 Inhibitory Leads via QSAR-Guided Selection of Crystallographic Pharmacophores Followed By In vitro Assay	Current Computer-Aided Drug Design	**2020**
29	Identification of the first “two digit nano-molar” inhibitors of the human glyoxalase-I enzyme as potential anticancer agents	Medicinal Chemistry	**2021**
30	Repurposing FDA-approved drugs against the "main protease" pivotal enzyme in COVID-19 virus using computer-aided drug design techniques	Preprint at Research Square	**2022**
31	Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores	Molecular Diversity	**2022**
32	Pharmacophore Modeling of Targets Infested with Activity Cliffs via Molecular Dynamics Simulation Coupled with QSAR and Comparison with other Pharmacophore Generation Methods: KDR as Case Study	Molecular Informatics	**2022**
33	Evaluation of antibacterial, antioxidant, cytotoxic, and acetylcholinesterase inhibition activities of novel [1,4] benzoxazepines	Medicinal Chemistry Research	**2022**

	fused to heterocyclic systems with a molecular modeling study		
34	Novel Sulfonamide−Triazine Hybrid Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	ACS Omega	**2023**
35	Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand- based pharmacophores and biological screening	Medicinal Chemistry Research	**2023**
36	In Silico Evaluation of Ferulic Acid Based Multifunctional Conjugates as Potential Drug Candidates	Medicinal Chemistry	**2023**
37	Novel hydantoin derivatives: Synthesis and biological activity evaluation	Results in Chemistry	**2023**
38	Docking, synthesis, and anticancer assessment of novel quinoline-amidrazone hybrids	Pharmacia	**2024**
39	Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer	Current Computer - Aided Drug Design	**2024**

	Protein		
40	Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	ACS Omega	**2024**
41	Synthesis, complexation, in vitro cholinesterase inhibitory activities and molecular docking of azinethiacrown ethers and acyclic thiacrown ethers derived indole	Journal of Molecular Structure	**2024**

Books:

#	Book Title	Publisher	Year
1.	*Discovery and optimization of new anticancer agents*	Scholars' press	**2015**
2	*تصميم الادوية وبناؤها*	ناشر: مؤسسة الامة العربية للنشر والتوزيع المقر الرئيسي : جمهورية مصر العربية رقم الايداع القانوني : 23543/2018 الرقم الدولي: 4/476/783/977/978 جهة الايداع: وزارة الثقافة المصرية 2018 سنة النشر 1440 ه- 2019	**2018**
3	*نظرة الى السرطان وطرق علاجه*	Amazon, , دار أسامة للنشر عمان	**2021**

Supervision of Theses:

#	Year	University	Thesis Title	Student Name

1.	*2017*	الجامعة الأردنية	Discovery and Optimzation of New KDR inhibitors	**الاء عزيز**
2	*2020*	جامعة الزرقاء	Synthesis of triazines as anticancer agents	**محمود عليمات**
3	*2021*	جامعة الزرقاء	Synthesis of Hydantoin derivatives as anticancer agents	**عبد الوهاب عقيل**
4	*2023*	جامعة الزرقاء	Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	**عمر مهدي**
5	*2023*	جامعة الزرقاء	DESIGN OF AMINOBENZOXAZOLE DERIVATIVES AS KDR INHIBITORS AND ANTI-CANCER AGENTS	**على خضر**
6	*2024*	جامعة الأسراء	Design, synthesis, characterization, and in-vitro evaluation of	**أماني سليمان**

			novel depigmenting agents	

Personal Information

Name	Mahmoud A.Al-Sha'er			
Place and Date of Birth	Libya, 30/3/1976			
Nationality	Jordanian			
Marital Status	Married			
Address	Amman-Jabal Al-Nuzha			
Work Tel No.	065 5 38 211 00			
Mobile:	0786844928			
Postal Address	13132 P.O.Box 132222 Faculty of Pharmacy	Zarqa University-Zarqa		